中国医疗前沿
中國醫療前沿
중국의료전연
CHINA HEALTHCARE INNOVATION
2013年
1期
86-87
,共2页
CA19-9%CEA%CA125%良恶性胰腺疾病
CA19-9%CEA%CA125%良噁性胰腺疾病
CA19-9%CEA%CA125%량악성이선질병
CA19-9%CEA%CA125%The benign and malignant diseases of pancreatic
目的探讨血清CA19-9、CEA和CA125对胰腺癌(pancreatic cancer,PC)、慢性胰腺炎(chronic pancreatitis,CP)鉴别诊断的临床价值.方法采用电化学发光免疫分析法检测60例胰腺癌患者(PC组),60例慢性胰腺炎患者(CP组)和60名健康体检者(对照组)外周血清CA19-9、CEA和CA125的表达水平,分析和比较肿瘤标志物单项和联合检测对胰腺癌的诊断价值.结果 PC组血清CA19-9、CEA和CA125的表达水平均明显高于CP组和对照组(P <0.01).CP组和对照组之间CA19-9、CEA和CA125比较差异无统计学意义(P >0.05).胰腺癌患者CA19-9、CEA和CA125敏感性分别为82.14%、47.36%、37.4%,特异性分别为53.26%、61.26%、63.15%.联合检测时敏感性、特异性分别为93.84%,95.68%.结论 CA19-9、CEA和CA125联合检测可以提高胰腺癌的诊断价值,有助于更好地鉴别良恶性胰腺疾病.
目的探討血清CA19-9、CEA和CA125對胰腺癌(pancreatic cancer,PC)、慢性胰腺炎(chronic pancreatitis,CP)鑒彆診斷的臨床價值.方法採用電化學髮光免疫分析法檢測60例胰腺癌患者(PC組),60例慢性胰腺炎患者(CP組)和60名健康體檢者(對照組)外週血清CA19-9、CEA和CA125的錶達水平,分析和比較腫瘤標誌物單項和聯閤檢測對胰腺癌的診斷價值.結果 PC組血清CA19-9、CEA和CA125的錶達水平均明顯高于CP組和對照組(P <0.01).CP組和對照組之間CA19-9、CEA和CA125比較差異無統計學意義(P >0.05).胰腺癌患者CA19-9、CEA和CA125敏感性分彆為82.14%、47.36%、37.4%,特異性分彆為53.26%、61.26%、63.15%.聯閤檢測時敏感性、特異性分彆為93.84%,95.68%.結論 CA19-9、CEA和CA125聯閤檢測可以提高胰腺癌的診斷價值,有助于更好地鑒彆良噁性胰腺疾病.
목적탐토혈청CA19-9、CEA화CA125대이선암(pancreatic cancer,PC)、만성이선염(chronic pancreatitis,CP)감별진단적림상개치.방법채용전화학발광면역분석법검측60례이선암환자(PC조),60례만성이선염환자(CP조)화60명건강체검자(대조조)외주혈청CA19-9、CEA화CA125적표체수평,분석화비교종류표지물단항화연합검측대이선암적진단개치.결과 PC조혈청CA19-9、CEA화CA125적표체수평균명현고우CP조화대조조(P <0.01).CP조화대조조지간CA19-9、CEA화CA125비교차이무통계학의의(P >0.05).이선암환자CA19-9、CEA화CA125민감성분별위82.14%、47.36%、37.4%,특이성분별위53.26%、61.26%、63.15%.연합검측시민감성、특이성분별위93.84%,95.68%.결론 CA19-9、CEA화CA125연합검측가이제고이선암적진단개치,유조우경호지감별량악성이선질병.
Objective To investigate the value of serum CA19-9, CEA and CA125 in diagnosing pancreatic cancer(PC) and chronic pancreatitis(CP). Methods Electrochemiluminescence immunoassay(ECL) was used to detected the peripheral serum levels of CA19-9, CEA and CA125 in 60 patients with pancreatic cancer(PC group), 60 patients with chronic pancreatitis(CP group) and 60 healthy individuals(control group). The comparison and analysis are made on the value of serum tumor markers in the diagnosis of pancreatic cancer by application of single and joint assay of CA19-9, CEA and CA125. Results The serum levels of CA19-9, CEA and CA125 in PC group were significantly higher than those in CP group and control group(P <0.01). CA19-9, CEA and CA125 were not significantly different between CP group and control group(P >0.05). The sensitivities of CA19-9, CEA and CA125 in patients with pancreatic cancer were 82.14%, 47.36% and 37.4%, while the specificities were 53.26%, 61.26% and 63.15%. The sensitivity and specificity of joint detection of CA19-9, CEA and CA125 were 93.84% and 95.68%. Conclusion The joint detection of CA19-9, CEA and CA125 can improve the diagnostic value of pancreatic cancer and may be helpful in the differential diagnosis of pancreatic cancer.
